PMID 18450759
In fact, a recent survey that we conducted with Harris Poll found that 86% of people who take GLP-1s experience side effects, including nausea, diarrhea, and constipation
No, or uncertain Chronic treatment may not be sustainable
CPP-CAND targets the well-ordered FOXO4 FHD domain, contributing to its high selectivity for senescent cells
Finding an inability of brand name GLP-1 manufacturers to keep up with patient demand for approved GLP-1 drugs, the FDA temporarily placed many of the approved GLP-1 drugs on the FDA shortage list, leading to an increase in the availability and sale of compounded drugs containing the active ingredient
Known for linking breakthroughs to real-world markets, he highlights how research transitions into products and industries that shape daily life.